Actively Recruiting

Early Phase 1
Age: 18Years +
All Genders
NCT07505771

A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

Led by Immunome, Inc. · Updated on 2026-04-06

105

Participants Needed

1

Research Sites

452 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

IM-3050-101 is a Phase 1 study to determine the safety and effectiveness of 177Lu-IM-3050 in treating participants with advanced cancer.

CONDITIONS

Official Title

A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years of age or older
  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1, or 2
  • Histological or cytological diagnosis of a solid tumor
  • Participants must be refractory to or have relapsed after at least one prior standard therapeutic regimen
  • Participants must be relapsed or refractory to, intolerant of, or not candidates for available therapies with established benefit
  • Participants must have measurable disease as per RECIST v.1.1 based on imaging performed during Screening
  • Participants must have positive FAP PET/CT uptake during screening
  • Participants must have adequate organ function
Not Eligible

You will not qualify if you...

  • Received certain prior radiation therapy as detailed in the protocol
  • Major surgery within 4 weeks or minor surgery within 2 weeks before starting 177Lu-IM-3050
  • Known active central nervous system (CNS) primary tumor, metastases, or carcinomatous meningitis
  • History of malignant primary brain tumor or other primary solid or hematologic malignancy unless disease-free for at least 3 years
  • Recent or ongoing serious infection or other significant medical condition as detailed in the protocol
  • Received an investigational product or device within 30 days or 5 half-lives prior to FAP PET/CT imaging tracer or 177Lu-IM-3050

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Excel Diagnostics and Nuclear Oncology Center

Houston, Texas, United States, 77042

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here